Page last updated: 2024-11-12

wwl70

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID17759121
CHEMBL ID4068554
SCHEMBL ID14684619
MeSH IDM0588994

Synonyms (24)

Synonym
4'-carbamoylbiphenyl-4-yl methyl(3-(pyridin-4-yl)benzyl)carbamate
wwl70
947669-91-2
wwl 70
4-(4-carbamoylphenyl)phenyl n-methyl-n-{[3-(pyridin-4-yl)phenyl]methyl}carbamate
gtpl5289
4'-carbamoyl-[1,1'-biphenyl]-4-yl methyl(3-(pyridin-4-yl)benzyl)carbamate
[4-(4-carbamoylphenyl)phenyl] n-methyl-n-[(3-pyridin-4-ylphenyl)methyl]carbamate
SCHEMBL14684619
n-methyl-n-[[3-(4-pyridinyl)phenyl]methyl]-4'-(aminocarbonyl)[1,1'-biphenyl]-4-yl carbamic acid ester
AKOS024457508
DTXSID40590859
4'-carbamoyl[1,1'-biphenyl]-4-yl methyl{[3-(pyridin-4-yl)phenyl]methyl}carbamate
wwl70, >=98% (hplc)
NCGC00370867-02
CS-8198
HY-100337
mfcd10567112
Q27089234
4'-carbamoyl-[1,1'-biphenyl]-4-yl methyl (3-(pyridin-4-yl)benzyl)carbamate
EX-A2937
CHEMBL4068554
MS-27841
XMB66991

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.19000.01237.983543.2770AID1645841
cytochrome P450 2D6Homo sapiens (human)Potency0.95220.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1460830Inhibition of ABHD6 in mouse BV2 cells preincubated for 30 mins and subsequent addition of [3H]-2-OG substrate measured after 15 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID1624798Inhibition of ABHD6 in mouse brain membrane assessed as protein band intensity at 10 uM pre-incubated for 25 mins followed by TAMRA-FP probe labeling for 5 mins by SDS-PAGE analysis relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.
AID1460831Inhibition of ABHD12 in mouse BV2 cells preincubated for 30 mins and subsequent addition of [3H]-2-OG substrate measured after 15 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID1910304Inhibition of ABHD6 in mouse brain membrane at 10 uM using TAMRA-FP serine hydrolase probe as substrate preincubated for 25 mins followed by substrate addition and measured after 25 mins SDS-PAGE analysis2022Journal of medicinal chemistry, 05-26, Volume: 65, Issue:10
Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives.
AID1624796Inhibition of FAAH in mouse brain membrane assessed as protein band intensity at 10 uM pre-incubated for 25 mins followed by TAMRA-FP probe labeling for 5 mins by SDS-PAGE analysis relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.
AID1624797Inhibition of MAGL in mouse brain membrane assessed as protein band intensity at 10 uM pre-incubated for 25 mins followed by TAMRA-FP probe labeling for 5 mins by SDS-PAGE analysis relative to control2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's3 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.26 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]